Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Follow-up After Oncological Resection by Endoscopic Colorectal ESD (Endoscopic Submucosal Dissection)

NCT07871227 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-10
Last updated
2026-10-16

Condition(s) studied

Colorectal Neoplasms

Investigational drug(s) / intervention(s)

Surgery, Radiochimiotherapy

Surgery, Radiochimiotherapy: Analysis of medical data and residual biological samples

Study summary

Colorectal cancer is a common and leading cause of death. Pre-cancerous lesions, as well as some so-called superficial cancers, can be resected via endoscopy. The technique chosen in the case of extensive lesions or superficial cancer is submucosal dissection. This technique helps avoid surgery, which has a higher morbidity and mortality (especially due to the non-preservation of the organ).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patient (18 years or older). * Presumed diagnosis of localized superficial colorectal cancer (T1) during endoscopy using the Conecct classification, confirmed by subsequent histopathological analysis. * Patient included in the French Colorectal ESD Cohort in Experts Centers (FECCo registry) since September 2019 for submucosal dissection. * Histological analysis of the resection specimen revealing a superficial colorectal adenocarcinoma with high risk of lymphatic recurrence, defined by at least one of the following criteria: submucosal invasion depth ≥ 1000 microns, tumor budding grade ≥ 2, presence of lymphatic and/or vascular emboli. Exclusion Criteria: * History of Crohn's disease (ICD-10: K50) or ulcerative colitis (ICD-10: K51). * History of familial adenomatous polyposis and/or genetic predisposition to colorectal cancer (ICD-10: D12.6+0/1/2/4/5 and 6). * Malignant tumor of the colon staged ≥ T2. * Patients not included in the FECCo registry. * Documented objection through the non-opposition form following review of the information notice

Primary outcome measure(s)

  • Recurrence-free survival — 12 months visit
    Proportion of patients who remain free of oncological recurrence, either locoregional and/or metastatic, at 12 months after ESD.

Trial sites (14)

FacilityCityRegionStatus
Clinique de l'Anjou Angers France
CHU Dijon Bourgogne Dijon France
CHU de Limoges Limoges France
Hospices civils de Lyon - Hôpital Edouard Herriot Lyon France
Clinique Jean Mermoz Lyon France
Clinique Jules Verne Nantes France
CHU Nîmes Nîmes France
AP-HP Hôpital Cochin Paris France
Paris Saint Joseph Paris France
AP-HP Hôpital Européen Georges-Pompidou Paris France
CHU de Bordeaux Pessac France
CHU de Rennes Rennes France
Clinique Santé Atlantique Saint-Herblain France
CHRU de Nancy Vandœuvre-lès-Nancy France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07871227 on ClinicalTrials.gov ↗ ← All trials in France